TY - JOUR
T1 - What do we know about dynamic glucose-enhanced (DGE) MRI and how close is it to the clinics? Horizon 2020 GLINT consortium report
AU - the GLINT consortium
AU - Kim, Mina
AU - Eleftheriou, Afroditi
AU - Ravotto, Luca
AU - Weber, Bruno
AU - Rivlin, Michal
AU - Navon, Gil
AU - Capozza, Martina
AU - Anemone, Annasofia
AU - Longo, Dario Livio
AU - Aime, Silvio
AU - Zaiss, Moritz
AU - Herz, Kai
AU - Deshmane, Anagha
AU - Lindig, Tobias
AU - Bender, Benjamin
AU - Golay, Xavier
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/2
Y1 - 2022/2
N2 - Cancer is one of the most devastating diseases that the world is currently facing, accounting for 10 million deaths in 2020 (WHO). In the last two decades, advanced medical imaging has played an ever more important role in the early detection of the disease, as it increases the chances of survival and the potential for full recovery. To date, dynamic glucose-enhanced (DGE) MRI using glucose-based chemical exchange saturation transfer (glucoCEST) has demonstrated the sensitivity to detect both d-glucose and glucose analogs, such as 3-oxy-methyl-d-glucose (3OMG) uptake in tumors. As one of the recent international efforts aiming at pushing the boundaries of translation of the DGE MRI technique into clinical practice, a multidisciplinary team of eight partners came together to form the “glucoCEST Imaging of Neoplastic Tumors (GLINT)” consortium, funded by the Horizon 2020 European Commission. This paper summarizes the progress made to date both by these groups and others in increasing our knowledge of the underlying mechanisms related to this technique as well as translating it into clinical practice.
AB - Cancer is one of the most devastating diseases that the world is currently facing, accounting for 10 million deaths in 2020 (WHO). In the last two decades, advanced medical imaging has played an ever more important role in the early detection of the disease, as it increases the chances of survival and the potential for full recovery. To date, dynamic glucose-enhanced (DGE) MRI using glucose-based chemical exchange saturation transfer (glucoCEST) has demonstrated the sensitivity to detect both d-glucose and glucose analogs, such as 3-oxy-methyl-d-glucose (3OMG) uptake in tumors. As one of the recent international efforts aiming at pushing the boundaries of translation of the DGE MRI technique into clinical practice, a multidisciplinary team of eight partners came together to form the “glucoCEST Imaging of Neoplastic Tumors (GLINT)” consortium, funded by the Horizon 2020 European Commission. This paper summarizes the progress made to date both by these groups and others in increasing our knowledge of the underlying mechanisms related to this technique as well as translating it into clinical practice.
KW - 3-Oxy-methyl-d-glucose
KW - CEST
KW - Cancer
KW - DGE MRI
KW - Glucose
KW - MRI
KW - glucoCEST
UR - http://www.scopus.com/inward/record.url?scp=85123441205&partnerID=8YFLogxK
U2 - 10.1007/s10334-021-00994-1
DO - 10.1007/s10334-021-00994-1
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 35032288
AN - SCOPUS:85123441205
SN - 0968-5243
VL - 35
SP - 87
EP - 104
JO - Magnetic Resonance Materials in Physics, Biology, and Medicine
JF - Magnetic Resonance Materials in Physics, Biology, and Medicine
IS - 1
ER -